CDSCO Panel Grants Novartis Protocol Amendment Proposal For Ianalumab
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis' protocol amendment proposal for the drug Ianalumab (VAY736). This came after Novartis presented …